Triumeq Dosage/Direction for Use

Therapy should be prescribed by a physician experienced in the management of HIV infection.
Posology: Adults and adolescents (weighing at least 40kg): The recommended dose of Triumeq in adults and adolescents is one tablet once daily.
Triumeq should not be administered to adults or adolescents who weigh less than 40 kg because it is a fixed-dose tablet that cannot be dose reduced.
Triumeq is a fixed-dose tablet and should not be prescribed for patients requiring dose adjustments. Separate preparations of dolutegravir, abacavir or lamivudine are available in cases where discontinuation or dose adjustment of one of the active substances is indicated. In these cases the physician should refer to the individual product information for these medicinal products.
Missed doses: If the patient misses a dose of Triumeq, the patient should take it as soon as possible, providing the next dose is not due within 4 hours. If the next dose is due within 4 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.
Elderly: There are limited data available on the use of dolutegravir, abacavir and lamivudine in patients aged 65 years and over. There is no evidence that elderly patients require a different dose than younger adult patients (see Pharmacology: Pharmacokinetics under Actions). Special care is advised in this age group due to age associated changes such as the decrease in renal function and alteration of haematological parameters.
Renal impairment: Triumeq is not recommended for use in patients with a creatinine clearance < 50 ml/min (see Pharmacology: Pharmacokinetics under Actions).
Hepatic impairment: Abacavir is primarily metabolised by the liver. No clinical data are available in patients with moderate or severe hepatic impairment, therefore the use of Triumeq is not recommended unless judged necessary. In patients with mild hepatic impairment (Child-Pugh score 5-6) close monitoring is required, including monitoring of abacavir plasma levels if feasible (see Precautions and Pharmacology: Pharmacokinetics under Actions).
Paediatric population: The safety and efficacy of Triumeq in children less than 12 years of age has not yet been established. No data are available.
Method of administration: Oral use.
Triumeq can be taken with or without food (see Pharmacology: Pharmacokinetics under Actions).